Alzheimer's Disease Education and Referral Center

Search for Clinical Trials

Your Search Identified 80 Trial(s):

  • 1. AC-1204 for Mild to Moderate Alzheimer's Disease

    Purpose: To evaluate the effects of AC-1204 on cognition, activities of daily living, quality of life, pharmacokinetic measures, and safety in people with mild to moderate Alzheimer's disease.

  • 2. Aerobic & Cognitive Exercise Study (ACES)

    Purpose: To clarify the benefits to brain health and thinking processes that result from different forms of exercise.

  • 3. Alzheimer's Biomarkers in African Americans

    Purpose: To determine the influence of Alzheimer's disease and vascular disease on memory and aging in African Americans through biomarkers.

  • 4. Alzheimer's Caregiver Coping: Mental and Physical Health

    Purpose: To compare two intervention strategies for reducing emotional and cardiovascular disease risk in Alzheimer's caregivers.

  • 5. Alzheimer's Disease Genetics Study

    Purpose: To identify the genes that are responsible for causing Alzheimer's disease by collecting genetic material from families with multiple members diagnosed with Alzheimer's disease.

  • 6. Alzheimer's Disease Multiple Intervention Trial

    Purpose: To improve functioning among older adults with Alzheimer's disease by comparing a control group receiving best practices primary care with an intervention group receiving best practice primary care plus a home-based occupational therapy intervention.

  • 7. Alzheimer's Prevention Through Exercise

    Purpose: To learn about the possible benefits of aerobic exercise for individuals at risk of developing Alzheimer's disease.

  • 8. Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4)

    Purpose: To test whether an anti-amyloid investigational drug, solanezumab, can slow memory and cognitive decline in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia.

  • 9. Arterial Spin Labeling (ASL) MRI for Cognitive Decline

    Purpose: To determine the value of arterial spin labeling magnetic resonance imaging, a measure of blood flow to the brain, in finding the cause of cognitive decline in people with mild cognitive impairment.

  • 10. AZD0530 in Mild Alzheimer's Disease (Connect Study)

    Purpose: To determine the safety and efficacy of the experimental drug AZD0530 in older adults with mild Alzheimer's disease.

  • 11. AZD3293 in Early Alzheimer's Disease (AMARANTH)

    Purpose: To assess the efficacy and safety of AZD3293 as a possible treatment for early Alzheimer´s disease.

  • 12. BAN2401 for Early Alzheimer's Disease

    Purpose: To determine the effectiveness of the experimental drug BAN2401 as a possible treatment for people with mild cognitive impairment or mild Alzheimer's disease.

  • 13. Behavioral Interventions to Prevent or Delay Dementia

    Purpose: To compare the effectiveness of different combinations of five behavioral interventions in people with amnestic mild cognitive impairment.

  • 14. BIIB037 in Prodromal or Mild Alzheimer's Disease

    Purpose: To evaluate the safety and tolerability of BIIB037 in people with prodromal or mild Alzheimer's disease.

  • 15. Brain Alterations and Cognitive Impairment in Older Adults with Heart Failure

    Purpose: To study the relationship between brain MRI results and cognitive impairment in older adults with heart failure.

  • 16. Brexpiprazole for Agitation in Alzheimer's Dementia

    Purpose: To assess the efficacy of the experimental drug brexpiprazole in people with agitation due to Alzheimer's dementia.

  • 17. Carvedilol in Alzheimer's Disease

    Purpose: To determine whether carvedilol treatment is associated with improvement in Alzheimer's disease compared to a placebo.

  • 18. Cataract Removal and Alzheimer's Disease

    Purpose: To determine if cataract removal will improve the quality of life, vision, and cognition in people with Alzheimer's disease.

  • 19. Cholinesterase Inhibitor Discontinuation

    Purpose: To determine if stopping certain medications for Alzheimer's disease will cause worsened cognition, functioning, or behavior in veterans with advanced dementia.

  • 20. Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

    Purpose: To standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden.

  • 21. Coconut Oil for Alzheimer's Disease

    Purpose: To determine the efficacy of coconut oil as a possible treatment for mild to moderate Alzheimer's disease.

  • 22. Cognitive Benefits of Aerobic Exercise Across the Age Span

    Purpose: To test the hypothesis that aerobic exercise leads to improved cognitive function.

  • 23. Cognitive Training and Practice Effects in MCI

    Purpose: To test the effectiveness of a computerized cognitive (thinking) training program in people with mild cognitive impairment.

  • 24. Cognitive Video Game Performance in Healthy Older Adults

    Purpose: To evaluate the difference in learning and performance measures associated with using a video game in healthy older adults.

  • 25. Crenezumab for Mild to Moderate Alzheimer Disease

    Purpose: To evaluate the safety and tolerability of crenezumab in older adults with mild to moderate Alzheimer's disease.

  • 26. Curcumin and Yoga Therapy for Mild Cognitive Impairment

    Purpose: To test the clinical benefits of curcumin, a compound isolated from turmeric root, and a yoga-based physical exercise program in individuals with early memory problems.

  • 27. Dominantly Inherited Alzheimer Network (DIAN)

    Purpose: To identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

  • 28. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia (DIAN TU)

    Purpose: To assess the safety, tolerability, and biomarker efficacy of gantenerumab and solanezumab in individuals who have a genetic mutation for autosomal-dominant Alzheimer's disease.

  • 29. E2609 for Mild Cognitive Impairment Due to Alzheimer's Disease

    Purpose: To evaluate the safety and efficacy of the experimental drug E2609 in people with mild cognitive impairment or mild dementia due to Alzheimer's disease.

  • 30. Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease

    Purpose: To study vascular risk factors that cause memory and thinking problems and ways to control these risk factors.

  • 31. EEG Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES)

    Purpose: To determine whether, compared with usual anesthetic care, an EEG-guided anesthesia protocol can prevent delirium after surgery.

  • 32. Effect of Blueberries on Cognition and Body Composition in Elderly with Mild Cognitive Decline

    Purpose: To examine the effect of blueberry consumption on cognitive decline and body composition in older adults with mild cognitive decline.

  • 33. Effect of NeuroAD on Cognitive Function in Alzheimer's Disease

    Purpose: To test the effect of NeuroAD, a noninvasive device that delivers magnetic stimulation to the brain, on cognition in people with Alzheimer's disease.

  • 34. Effects of a Lutein Supplement on Cognitive Function

    Purpose: To determine the effects of taking lutein, a dietary supplement, on cognition in adults of all ages.

  • 35. Effects of Aging and Estrogen on Memory and Cognition

    Purpose: To examine the impact of aging on functional changes induced by estrogen in parts of the brain associated with memory

  • 36. Effects of Anesthesia on Cognition and Alzheimer's Disease Biomarkers

    Purpose: To evaluate the effects of surgical anesthesia on cognition and certain Alzheimer's disease biomarkers in older adults who undergo surgery.

  • 37. Effects of Atomoxetine in Mild Cognitive Impairment

    Purpose: To find out if atomoxetine causes a change in the biomarkers (substances that may indicate the presence of a disease) in the cerebrospinal fluid of people diagnosed with mild cognitive impairment.

  • 38. Effects of Brain Beta-Amyloid on Postoperative Cognition

    Purpose: To determine if the presence of beta-amyloid plaques in the brains of non-demented patients before hip or knee replacement surgery predicts cognitive decline after surgery.

  • 39. Effects of Donepezil Measured by Functional MRI

    Purpose: To examine the sensitivity of functional MRI to detect brain changes in healthy older adults at genetic risk for Alzheimer's disease who take donepezil (Aricept).

  • 40. Effects of Fruitflow-II and Resveratrol on Memory, Fitness, and Cerebral Blood Flow

    Purpose: To determine if Fruitflow-II (a tomato extract), resveratrol (a compound found in some foods), alone or in combination, can effectively treat memory problems in older adults with memory impairment.

  • 41. Evaluation of Tracers for Positron Emission Tomography (PET) Imaging of Tau

    Purpose: To obtain basic information about three PET imaging tracers developed to detect tau pathology in the brain.

  • 42. EVP-6124 for Treating Alzheimer's Disease

    Purpose: To evaluate the safety and efficacy of EVP-6124 as a potential treatment for mild to moderate Alzheimer's disease.

  • 43. Exendin-4 in Alzheimer's Disease

    Purpose: To determine the safety and effectiveness of twice daily administration of Exendin-4 as a treatment for early-stage Alzheimer's disease or mild cognitive impairment.

  • 44. Exercise, Age-Related Memory Decline, and Hippocampal Function

    Purpose: To test the hypothesis that aerobic exercise leads to increased blood volume in the brain, specifically in the dentate gyrus of the hippocampus.

  • 45. FRM-0334 for Frontotemporal Dementia with a Granulin Mutation

    Purpose: To investigate the safety, tolerability, and pharmacodynamics of the experimental drug FRM-0334 in people with early to moderate frontotemporal dementia with a granulin mutation.

  • 46. Gantenerumab for Mild Alzheimer Disease

    Purpose: To evaluate the efficacy and safety of the experimental drug gantenerumab as a possible treatment for people with mild Alzheimer disease.

  • 47. Gemfibrozil in Predementia Alzheimer's Disease

    Purpose: To assess the drug gemfibrozil for the prevention of Alzheimer's disease.

  • 48. Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)

    Purpose: To learn more about biomarkers and their relationship to aging.

  • 49. Home-Delivered Intervention for Depressed, Cognitively Impaired Elders

    Purpose: To test the efficacy of Problem Adaptation Therapy (PATH), a home-delivered psychosocial intervention for elders with major depression, memory problems, and disability.

  • 50. Human Brain Antioxidants During Oxidative Stress

    Purpose: To evaluate the level of two antioxidants in the brain as humans with and without Alzheimer's disease get older.

  • 51. Imaging of Cognition, Learning, and Memory in Aging

    Purpose: To study how the brain functions when it performs explicit memory tasks and how this changes as a function of aging.

  • 52. Improving Dementia Caregiver Sleep and the Effect on Heart Disease Biomarkers

    Purpose: To determine whether a combined intervention of a nighttime home monitoring system and cognitive-behavioral therapy for insomnia is effective in improving sleep in dementia caregivers who arise at night.

  • 53. Indiana University Dementia Screening Trial

    Purpose: To assess the harms and benefits of screening for dementia, compared to no screening for dementia, among older adults in a primary care setting.

  • 54. Language in Primary Progressive Aphasia

    Purpose: To further define the neurological and linguistic deterioration in primary progressive aphasia.

  • 55. Lidocaine for Neuroprotection During Cardiac Surgery

    Purpose: To see if the drug lidocaine can prevent cognitive decline after heart surgery.

  • 56. Living with Frontotemporal Dementia

    Purpose: To better understand the experience of people with frontotemporal dementia and their caregivers in order to develop better therapies.

  • 57. MEDI1814 for Mild to Moderate Alzheimer's Disease

    Purpose: To assess the safety and efficacy of the drug MEDI1814 in people with mild to moderate Alzheimer's disease.

  • 58. Memory Consolidation in Obstructive Sleep Apnea

    Purpose: To test the use of continuous positive airway pressure (CPAP) to reverse some or all memory deficits in people with obstructive sleep apnea.

  • 59. Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)

    Purpose: To determine whether positron emission tomography (PET) scanning can help distinguish patients with early Alzheimer's changes in their brains from those having other causes of cognitive impairment more accurately than current clinical practices.

  • 60. Mild Cognitive Impairment in Breast Cancer

    Purpose: To study how women undergoing breast cancer treatment may develop brain changes related to the development of mild cognitive impairment.

  • 61. MK-7622 in People with Alzheimer's Disease Taking Donepezil

    Purpose: To test the efficacy and safety of MK-7622 as an add-on therapy to donepezil in people with mild to moderate Alzheimer's disease.

  • 62. MK-8931 for Amnestic Mild Cognitive Impairment (APECS)

    Purpose: To assess MK-8931 as a possible treatment for amnestic mild cognitive impairment due to Alzheimer's disease.

  • 63. MK-8931 for Mild to Moderate Alzheimer's Disease

    Purpose: To assess the efficacy and safety of MK-8931 as a possible treatment for Alzheimer's disease.

  • 64. Natural History of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

    Purpose: To characterize the natural history of disease in people who carry a repeat expansion in the C9ORF72 gene, which causes amyotrophic lateral sclerosis and frontotemporal dementia.

  • 65. NOBLE: T-817MA for Mild to Moderate Alzheimer's Disease

    Purpose: To evaluate the efficacy of the experimental drug T-817MA as a potential treatment for people with mild to moderate Alzheimer's disease.

  • 66. Nuedexta for Treating Pseudobulbar Affect in Alzheimer's Disease

    Purpose: To test the safety and effectiveness of the drug Nuedexta (dextromethorphan/quinidine) as a treatment for pseudobulbar affect in people with Alzheimer's disease.

  • 67. Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Older Adults

    Purpose: To determine if a worsened sense of smell can identify older people who might benefit from treatment with the Alzheimer's drug donepezil.

  • 68. PET Imaging with 18F-AV-1451

    Purpose: To evaluate the characteristics of the brain imaging agent 18F-AV-1451 in cognitively healthy volunteers and in people with mild cognitive impairment or Alzheimer's disease.

  • 69. PET Imaging with [18F]XTRA

    Purpose: To test the ability of the imaging agent [18F]XTRA to detect early brain changes in neurodegenerative diseases such as Alzheimer's.

  • 70. Pharmacological Management of Delirium (PMD)

    Purpose: To develop and test the feasibility of using a specific pharmacological protocol to reduce delirium among older adults in the intensive care unit.

  • 71. Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

    Purpose: To study the effectiveness of prazosin treatment for people with Alzheimer's disease or a related dementia who have difficult behaviors.

  • 72. Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment

    Purpose: To test the effects of transcranial direct current stimulation on memory in people with mild cognitive impairment.

  • 73. Rasagiline in Alzheimer's Disease

    Purpose: To evaluate the effect of the drug rasagiline on brain metabolism in people with mild to moderate Alzheimer's disease.

  • 74. Reducing Agitation in People with Dementia

    Purpose: To test a nonpharmacologic intervention, the Tailored Activity Program, for reducing agitation in people with dementia.

  • 75. Reliability of the Human Brain Connectome

    Purpose: To use magnetic resonance imaging to investigate brain function and connections in healthy adults.

  • 76. Screening and Evaluation of Patients with Signs and Symptoms of Alzheimer's Disease

    Purpose: To determine whether a person meets the eligibility criteria to participate in an Alzheimer's disease research study.

  • 77. Sleep-Disordered Breathing and Alzheimer's Disease Prevention (SNAP)

    Purpose: To examine the relationship between sleep-disordered breathing and Alzheimer's disease in cognitive normal older adults.

  • 78. SUVN-G3031 Safety, Tolerability, and Pharmacokinetics

    Purpose: To investigate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy subjects.

  • 79. Transcranial Magnetic Stimulation to Treat Alzheimer's

    Purpose: To test transcranial magnetic stimulation as a treatment for Alzheimer's disease.

  • 80. VA Cultivating Access to Resources, Education, and Skills for Dementia Caregivers (VA CARES)

    Purpose: To study the effects of an education and skill-building intervention on family caregivers of veterans with dementia.

  • Return to AD Clinical Trials Search Results

    Return to AD Clinical Trials Home

    Refine Your Search

    Type in a word or phrase such as drug name,
    disease stage, or trial name
    Input a city and state or zip code
    Enter the distance in number of miles from the location
    (default is 50)
    Age of the participant